Emcure Pharmaceuticals Ltd.
EMCURE
Rank in Stocks
#4306
Emcure Pharmaceuticals Limited is committed to providing high-quality,... Emcure Pharmaceuticals Limited is committed to providing high-quality, cost-effective healthcare solutions to a global market. The company boasts a diverse product lineup spanning numerous medical fields, such as women's health (gynecology), anti-infectives, pain relief, nutritional supplements (vitamins, minerals, and nutrients), hematology, oncology, respiratory treatments, HIV antivirals, gastrointestinal remedies, anti-diabetics, neurological medications, and cardiovascular therapies. Notable brand names under their umbrella include Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym. Founded in 1981, Emcure Pharmaceuticals Limited is headquartered in Pune, India.
Share Price
$19.00
Market Cap
$3.60B
Change (1 day)
-2.14%
Change (1 year)
20.12%
Country
IN
Trade Emcure Pharmaceuticals Ltd. (EMCURE)
Category
Healthcare
P/S ratio for Emcure Pharmaceuticals Ltd. (EMCURE)
P/S ratio as of 2026 TTM: 0
According to Emcure Pharmaceuticals Ltd. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Emcure Pharmaceuticals Ltd. from 2025 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2025 | 2.58 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 7.06 | - |
IN
|
